Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 6/20 | 0.60 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.59 |
| ▸ | CKS1B | P61024 | 2/20 | 0.51 |
| ▸ | SKP1 | P63208 | 2/20 | 0.51 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25188353 | 1.00 | RET (0.60) | RETGPR119CKS1BSKP1SKP2 | |
| SCHEMBL16473496 | 0.85 | GPR119 (0.64) | RETGPR119CKS1BSKP1SKP2 | |
| SCHEMBL22581906 | 0.85 | GPR119 (0.60) | RETGPR119CKS1BSKP1SKP2 | |
| SCHEMBL30893593 | 0.84 | GPR119 (0.54) | RETGPR119CKS1BSKP1SKP2 | |
| SCHEMBL2122299 | 0.84 | GPR119 (0.54) | RETGPR119CKS1BSKP1SKP2 | |
| SCHEMBL25307735 | 0.84 | GPR119 (0.62) | RETGPR119CKS1BSKP1SKP2 | |
| SCHEMBL30620934 | 0.82 | GPR119 (0.60) | RETGPR119CKS1BSKP1SKP2 | |
| SCHEMBL7078017 | 0.82 | MAPT (0.60) | GPR119SMN1; SMN2 | |
| SCHEMBL30893577 | 0.82 | DDB1 (0.57) | RETGPR119CKS1BSKP1SKP2 | |
| SCHEMBL1905470 | 0.82 | DDB1 (0.57) | RETGPR119CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289800-A1 | Selective Parp1 Inhibitor And Application Thereof | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| EP-4434985-A1 | SELECTIVE PARP1 INHIBITOR AND APPLICATION THEREOF | Kangbaida (Sichuan) Biotechnology Co., Ltd. (CN) | 2024-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289800-A1 | Selective Parp1 Inhibitor And Application Thereof | PARP1, PARP11, PARP12 | RET 4049/4885GPR119 1130/4885CKS1B 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.